Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Renal Cell Cancer: early-phase trial registry
3 of 11 indexed Renal Cell Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,577 of 28,707 conditions by registered trial count.
11 US clinical trials · 3 currently recruiting · #1,577 of 28,707 conditions by registered trial count
Renal Cell Cancer: 11 US clinical trials tracked, 3 recruiting.
Renal Cell Cancer is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is Case Comprehensive Cancer Center, running 2 of these trials.
Enrollment posture brief
Registry condition renal-cell-cancer
OPEN 3 | RECR 27% | LATE 0 | EARLY 8 | RANK #1577 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Atherosclerotic Cardiovascular Disease (27% recruiting · 22 trials)
Renal Cell Cancer lists 3 open slots (27% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Renal Cell Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Renal Cell Cancer is recruiting below its size-band peers.
3 of 11 indexed trials (27.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Renal Cell Cancer research.
Case Comprehensive Cancer Center accounts for 2 of 11 trials (18.2%). 10 distinct sponsors appear on at least one study for this condition label.
-
Most Renal Cell Cancer trials plan to enrol fewer than 100 people.
Median target enrolment is 84 among the 11 trials that report a genuine target (sentinel values excluded). 7 of those (63.6%) plan for fewer than 100 participants.
-
Renal Cell Cancer research is mostly interventional.
9 interventional and 2 observational studies make up this index (81.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
11 total, page 1 of 1
A Study of IBI363 in Subjects with Advanced Solid Malignancies
Innovent Biologics (Suzhou) Co.
NCT06281678
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
National Cancer Institute (NCI)
NCT02830724
TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors
Portage Biotech
NCT04969315
Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors
Zhen Wang, MD
NCT04258462
Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer
Case Comprehensive Cancer Center
NCT04620603
NANOTECH RCC Biomarkers
Washington University School of Medicine
NCT02923284
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
Genentech
NCT01598597
Improving Outcomes in Cancer Patients on Oral Anti-Cancer Medications Using a Multi-modal Mobile Health Intervention
Massachusetts General Hospital
NCT02375776
Evaluate Safety and Tolerability in Dose Escalation of Sorafenib in Advanced Renal Cell Cancer
University of Kansas Medical Center
NCT01189370
Celecoxib and Recombinant Interferon Alfa-2b in Metastatic Kidney Cancer Who Have Undergone Surgery
Case Comprehensive Cancer Center
NCT01158534
Heated Chemotherapy for Cancers That Have Spread to the Chest Cavity
St. Luke's-Roosevelt Hospital Center
NCT01163552
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on Renal Cell Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Renal Cell Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Renal Cell Cancer page
11 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Renal Cell Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Case Comprehensive Cancer Center sponsors the most Renal Cell Cancer trials on record, review their full trial history before evaluating a specific study. See Case Comprehensive Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Renal Cell Cancer condition card totals 11 registered trials; most-linked intervention CORA- Device:smartphones"; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.